JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

Search

Eli Lilly and Co.

Fermé

SecteurSoins de santé

795.48 0.43

Résumé

Variation du prix de l'action

24h

Actuel

Min

785.34

Max

798.46

Chiffres clés

By Trading Economics

Revenu

-6.1B

2.8B

Ventes

-804M

13B

P/E

Moyenne du Secteur

62.756

50.291

BPA

3.34

Rendement du dividende

0.79

Marge bénéficiaire

21.678

Employés

47,000

EBITDA

-2B

4.2B

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+26.16% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.79%

2.40%

Prochains Résultats

6 août 2025

Date du Prochain Dividende

10 sept. 2025

Date du Prochain Détachement de Dividende

15 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-136B

692B

Ouverture précédente

795.05

Clôture précédente

795.48

Sentiment de l'Actualité

By Acuity

38%

62%

125 / 380 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Eli Lilly and Co. Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 juin 2025, 11:56 UTC

Acquisitions, Fusions, Rachats

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

27 mai 2025, 14:41 UTC

Acquisitions, Fusions, Rachats

Eli Lilly to Acquire SiteOne Therapeutics for Up to $1 Billion

17 juin 2025, 14:02 UTC

Acquisitions, Fusions, Rachats

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know. -- Barrons.com

17 juin 2025, 12:12 UTC

Acquisitions, Fusions, Rachats

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring 77%. What to Know. -- Barrons.com

17 juin 2025, 11:01 UTC

Acquisitions, Fusions, Rachats

This Stock Just Jumped 77% After Eli Lilly Made an Agreed $1.3 Billion Bid -- Barrons.com

17 juin 2025, 10:47 UTC

Acquisitions, Fusions, Rachats

Eli Lilly: Total Potential Consideration of Up to $13.50 Per Shr in Cash Without Interest >LLY

17 juin 2025, 10:47 UTC

Acquisitions, Fusions, Rachats

Eli Lilly: Considering Also Includes One Non-Tradeable Contingent Value Right Per Shr That Entitles Holder to Receive Up to an Additional $3 Per Shr >LLY

17 juin 2025, 10:46 UTC

Acquisitions, Fusions, Rachats

Eli Lilly Will Commence Tender Offer to Acquire All Outstanding Shrs of Verve for Purchase Price of $10.50 Per Shr in Cash >LLY

17 juin 2025, 10:45 UTC

Acquisitions, Fusions, Rachats

Lilly To Acquire Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

17 juin 2025, 09:33 UTC

Acquisitions, Fusions, Rachats

Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. -- Barrons.com

11 juin 2025, 09:45 UTC

Market Talk

Next Generation Obesity Drugs in Focus at American Diabetes Association Event -- Market Talk

29 mai 2025, 01:00 UTC

Actualités

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

28 mai 2025, 18:09 UTC

Résultats

Heart Disease Could Be a Goner When These New -2-

28 mai 2025, 18:09 UTC

Résultats

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

27 mai 2025, 14:02 UTC

Acquisitions, Fusions, Rachats

Eli Lilly: SiteOne Deal Includes Phase-2-Ready STC-004 for Treatment of Pain >LLY

27 mai 2025, 14:01 UTC

Acquisitions, Fusions, Rachats

Eli Lilly: SiteOne Deal Includes Upfront, Milestone Payments >LLY

27 mai 2025, 14:00 UTC

Acquisitions, Fusions, Rachats

Eli Lilly to Buy SiteOne Therapeutics For Up to $1 Billion in Cash >LLY

27 mai 2025, 14:00 UTC

Acquisitions, Fusions, Rachats

Lilly To Expand Its Pain Pipeline With Acquisition Of SiteOne Therapeutics >LLY

20 mai 2025, 14:08 UTC

Résultats

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

12 mai 2025, 22:14 UTC

Actualités

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mai 2025, 18:45 UTC

Actualités

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 mai 2025, 17:14 UTC

Actualités

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

7 mai 2025, 17:01 UTC

Actualités

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7 mai 2025, 13:56 UTC

Résultats

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7 mai 2025, 11:18 UTC

Résultats

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7 mai 2025, 09:30 UTC

Actualités

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

6 mai 2025, 20:30 UTC

Actualités

Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share. -- Barrons.com

4 mai 2025, 04:05 UTC

Acquisitions, Fusions, Rachats

UnitedHealth's Stock Is Ailing. A Bigger Business Hasn't Helped. -- Barrons.com

1 mai 2025, 21:07 UTC

Market Talk

Weight-Loss Drug Competitive Pressures Hammer Eli Lilly Shares -- Market Talk

1 mai 2025, 14:07 UTC

Résultats

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

Comparaison

Variation de prix

Eli Lilly and Co. prévision

Objectif de Prix

By TipRanks

26.16% hausse

Prévisions sur 12 Mois

Moyen 999.57 USD  26.16%

Haut 1,190 USD

Bas 700 USD

Basé sur 19 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

19 ratings

16

Achat

2

Maintien

1

Vente

Score Technique

By Trading Central

N/A / 884.54Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Strong Bearish Evidence

Sentiment

By Acuity

125 / 380Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.